Elevation Oncology Stock Year To Date Return
| ELEV Stock | USD 0.53 0.03 6.00% |
Elevation Oncology fundamentals help investors to digest information that contributes to Elevation Oncology's financial success or failures. It also enables traders to predict the movement of Elevation Stock. The fundamental analysis module provides a way to measure Elevation Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Elevation Oncology stock.
Elevation |
Elevation Oncology Company Year To Date Return Analysis
Elevation Oncology's Year to Date Return (YTD) is the total return generated from holding a security from the beginning of the current fiscal year. In other words, YTD Return represents the capital appreciation of your investments from the start of the current fiscal year.
More About Year To Date Return | All Equity Analysis
YTD Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Year-To-Date typically refers to a period starting from the beginning of the current year and continuing up to the present day. Investors should becareful when comparing YTD ratios if not much of the year has occurred as research shows that YTD measures are more sensitive to early periods than late.
| Competition |
According to the company's disclosures, Elevation Oncology has a Year To Date Return of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Portfolio Optimization Now
Portfolio OptimizationCompute new portfolio that will generate highest expected return given your specified tolerance for risk |
| All Next | Launch Module |
Elevation Fundamentals
| Return On Equity | -0.77 | ||||
| Return On Asset | -0.3 | ||||
| Current Valuation | (32.53 M) | ||||
| Shares Outstanding | 59.22 M | ||||
| Shares Owned By Insiders | 0.31 % | ||||
| Shares Owned By Institutions | 67.76 % | ||||
| Number Of Shares Shorted | 8.79 M | ||||
| Price To Earning | 0.16 X | ||||
| Price To Book | 0.49 X | ||||
| EBITDA | (44.7 M) | ||||
| Net Income | (44.48 M) | ||||
| Cash And Equivalents | 122.54 M | ||||
| Cash Per Share | 5.26 X | ||||
| Total Debt | 31.13 M | ||||
| Current Ratio | 6.48 X | ||||
| Book Value Per Share | 1.01 X | ||||
| Cash Flow From Operations | (36.36 M) | ||||
| Short Ratio | 6.75 X | ||||
| Earnings Per Share | (0.78) X | ||||
| Target Price | 7.0 | ||||
| Number Of Employees | 34 | ||||
| Beta | 1.38 | ||||
| Market Capitalization | 29.52 M | ||||
| Total Asset | 95.63 M | ||||
| Retained Earnings | (240.46 M) | ||||
| Working Capital | 90.26 M | ||||
| Net Asset | 95.63 M |
About Elevation Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Elevation Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Elevation Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Elevation Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Elevation Stock Analysis
When running Elevation Oncology's price analysis, check to measure Elevation Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elevation Oncology is operating at the current time. Most of Elevation Oncology's value examination focuses on studying past and present price action to predict the probability of Elevation Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elevation Oncology's price. Additionally, you may evaluate how the addition of Elevation Oncology to your portfolios can decrease your overall portfolio volatility.